TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9232135

Group type: COMPARATOR
Intervention: Low intracuff pressure (30 mmHg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High intracuff pressure (180 mmHg)
Number of subjects: 70
Study: 8489326

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate (average dose, 60 mg/d)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Haloperidol (average dose, 4 mg/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 3031150

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone for group A
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Corticotropin (ACTH) for group B
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prolonging therapy beyond 10 days by switching to the alternate corticoid drug
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Initial therapy period
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuing therapy beyond initial treatment
Number of subjects: 66
Study: 29558423

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification programme (ILMP)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: GA + Metformin (GA + Met)
Number of subjects: 294

Group type: COMPARATOR
Intervention: General advice (GA)
Number of subjects: 294
Study: 25864773

Group type: EXPERIMENTAL
Intervention: DBT-informed skills training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 41
Study: 24841548

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 835
Study: 22124612

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (E-I test quadrants) induced by oral hygiene abstention for 21 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control quadrant with routine oral hygiene (E-I control quadrants)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (E-I test quadrants)
Number of subjects: 37

Group type: COMPARATOR
Intervention: N-O gingivitis
Number of subjects: 37
Study: 23057264

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4L/min
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no supplemental oxygen)
Number of subjects: 70
Study: 18568324

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) 1.5 mL/kg administered into CPB priming fluid and pumped via CPB after aorta unclamping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) 1.5 mL/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no SFI)
Number of subjects: 40
Study: 15768198

Group type: COMPARATOR
Intervention: Spontaneous baroreflex sensitivity (BRS) in ESRD patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Temporal QT variability index (QTVI) in ESRD patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Within-subject reproducibility of BRS measurements
Number of subjects: 46

Group type: COMPARATOR
Intervention: Within-subject reproducibility of QTVI measurements
Number of subjects: 46

Group type: COMPARATOR
Intervention: Coefficient of variation (CV) of within-subject reproducibility of BRS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Coefficient of variation (CV) of within-subject reproducibility of QTVI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Concordance correlation coefficients of within-subject variability of BRS and QTVI
Number of subjects: 46

Group type: COMPARATOR
Intervention: CV of intra- and inter-examiner reproducibility of BRS and QTVI measurements
Number of subjects: 46
Study: 12453707

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (SI)
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 5887
Study: 10360371

Group type: EXPERIMENTAL
Intervention: Lisofylline (3 mg/kg every 6 h i.v.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7618448

Group type: EXPERIMENTAL
Intervention: Intravenous MgS04 therapy
Number of subjects: 0
Study: 1786587

Group type: EXPERIMENTAL
Intervention: Olbetam (250 mg 3 x per day for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7222718

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 1000 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 16
Study: 31351488

Group type: EXPERIMENTAL
Intervention: Low-dose bio-optimized Curcuma longa extract (BCL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose bio-optimized Curcuma longa extract (BCL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study: 30195629

Group type: EXPERIMENTAL
Intervention: Coconut water
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Meat sandwich
Number of subjects: 17
Study: 26901576

Group type: EXPERIMENTAL
Intervention: PedaTyph™ vaccine (2 doses at 6 weeks interval)
Number of subjects: 1765

Group type: COMPARATOR
Intervention: Control group (vaccines as per national guidelines)
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: PedaTyph™ vaccine
Number of subjects: 1765
Study: 24986785

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 563
Study: 22241898

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (anthracycline-based)
Number of subjects: 823

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Nuclear p27 expression
Number of subjects: 823
Study: 21180797

Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (MTA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silver amalgam without zinc (Am)
Number of subjects: 80
Study: 17392721

Group type: EXPERIMENTAL
Intervention: Laropiprant 30, 100, and 300 mg coadministered with extended-release niacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15911904

Group type: EXPERIMENTAL
Intervention: Written disclosure condition
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 94
Study: 11919330

Group type: EXPERIMENTAL
Intervention: 1 mL 33% oral glucose given 2 min before the heel prick
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: sucking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mL 33% oral glucose plus sucking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: multisensory stimulation including 1 mL 33% oral glucose
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: multisensory stimulation without oral glucose
Number of subjects: 120

Group type: COMPARATOR
Intervention: control
Number of subjects: 120
Study: 10067815

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication followed by daily dietary supplementation with antioxidant micronutrients
Number of subjects: 863
Study: 7564362

Group type: EXPERIMENTAL
Intervention: Combination therapy (5 mg ramipril and 6 mg piretanide)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Piretanide monotherapy
Number of subjects: 611

Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 611

Group type: COMPARATOR
Intervention: Piretanide therapy
Number of subjects: 611

Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 611
Study: 2188796

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1000 mg twice daily (or 2000 mg once daily) for 10 to 15 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cefadroxil 1000 mg twice daily for 10 to 15 days
Number of subjects: 55
Study: 6969559

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg intravenously every 6 hours for four doses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29956019

Group type: EXPERIMENTAL
Intervention: WBV + RE
Number of subjects: 9

Group type: COMPARATOR
Intervention: RE
Number of subjects: 9
Study: 28596274

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (70 ml, 0.4 g nitrate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nitrate-depleted (70 ml, 0 g nitrate)
Number of subjects: 6
Study: 25901481

Group type: EXPERIMENTAL
Intervention: Remoxy 20 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Remoxy 10 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Remoxy (both doses)
Number of subjects: 39
Study: 23843053

Group type: EXPERIMENTAL
Intervention: Resistance Training Group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Aerobic Exercise Group
Number of subjects: 96
Study: 21245884

Group type: EXPERIMENTAL
Intervention: Dietary α‐tocopherol
Number of subjects: 25005

Group type: EXPERIMENTAL
Intervention: Dietary β‐tocopherol
Number of subjects: 25005

Group type: EXPERIMENTAL
Intervention: Dietary β‐tocotrienol
Number of subjects: 25005
Study: 18852682

Group type: EXPERIMENTAL
Intervention: Parallel texture orientations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthogonal texture orientations
Number of subjects: 0
Study: 17568798

Group type: EXPERIMENTAL
Intervention: Different types of UVB radiation
Number of subjects: 0
Study: 15547060

Group type: EXPERIMENTAL
Intervention: Community based exercise programme
Number of subjects: 6416

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6416
Study: 15766363

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (for systemic antibiotics)
Number of subjects: 16
Study: 10599953

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8735994

Group type: EXPERIMENTAL
Intervention: Blocked practice schedule
Number of subjects: 83

Group type: COMPARATOR
Intervention: Alternating practice schedule
Number of subjects: 83
Study: 1759491

Group type: EXPERIMENTAL
Intervention: 10 micrograms PTxd
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 50 micrograms PTxd
Number of subjects: 101

Group type: COMPARATOR
Intervention: DTP
Number of subjects: 101
Study: 6750068

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31975502

Group type: COMPARATOR
Intervention: Topical serum containing vitamin C (20% w/w), vitamin E, and raspberry leaf cell culture extract applied on one side of the face for 2 months.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical serum containing vitamin C, vitamin E, and raspberry leaf cell culture extract
Number of subjects: 50
Study: 30100336

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1000 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous dexketoprofen 50 mg
Number of subjects: 200
Study: 27830924

Group type: EXPERIMENTAL
Intervention: Hatha Yoga (HY)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional Training Program (CTP)
Number of subjects: 36
Study: 25557731

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% fractional inspired O2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normoxia (21% fractional inspired O2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (healthy adults)
Number of subjects: 15
Study: 24290977

Group type: EXPERIMENTAL
Intervention: Minimal-access carpal tunnel release (MACTR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional open carpal tunnel release (TOCTR)
Number of subjects: 120
Study: 21114791

Group type: EXPERIMENTAL
Intervention: HMPL-004 1200 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mesalazine 4500 mg/day
Number of subjects: 120
Study: 19526394

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18049171

Group type: EXPERIMENTAL
Intervention: Midazolam (2.87±0.67 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Midazolam (1.82±0.71 mg) with Meperidine (42.81±14.61 mg)
Number of subjects: 48
Study: 15453924

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan
Number of subjects: 143

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (in patients achieving CR/CRu)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Rituximab (in patients achieving CR/CRu)
Number of subjects: 143
Study: 11438320

Group type: EXPERIMENTAL
Intervention: Repronex SC
Number of subjects: 115

Group type: COMPARATOR
Intervention: Repronex IM
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pergonal IM
Number of subjects: 115
Study: 9539992

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 7527170

Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400 mg lomefloxacin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400 mg lomefloxacin followed by 400 mg daily for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis
Number of subjects: 60
Study: 30139908

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 0
Study: 27668698

Group type: EXPERIMENTAL
Intervention: 15 mg propiverine hydrochloride (P4) t.i.d. from day 1 to day 7
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched placebo (PL)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 15 mg propiverine hydrochloride (P4)
Number of subjects: 48
Study: 25556817

Group type: EXPERIMENTAL
Intervention: Glucose-fructose (GF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose-only (G)
Number of subjects: 20
Study: 23743458

Group type: EXPERIMENTAL
Intervention: Three video teaching sessions with University of California, San Francisco faculty
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 18
Study: 21967940

Group type: EXPERIMENTAL
Intervention: Fluoridated paste (Dentsply, York, Pa)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Plain pumice (Ortho Technology, Tampa, Fla)
Number of subjects: 34
Study: 18155504

Group type: EXPERIMENTAL
Intervention: Continuous wave obturation with ProFile 29 Series rotary system
Number of subjects: 36

Group type: COMPARATOR
Intervention: Endo‐Eze system
Number of subjects: 36
Study: 16938024

Group type: EXPERIMENTAL
Intervention: Auditory linguistic cues
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Visual linguistic cues
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Auditory and visual linguistic cues with distractors
Number of subjects: 91
Study: 14512131

Group type: EXPERIMENTAL
Intervention: Breath holding for 0 seconds
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Breath holding for 3 seconds
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Breath holding for 10 seconds
Number of subjects: 21
Study: 10829313

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy combined with surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 9352870

Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) therapy
Number of subjects: 103
Study: 8408979

Group type: EXPERIMENTAL
Intervention: Morning light treatment (ML)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Evening light treatment (EL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both ML and EL
Number of subjects: 27
Study: 3955198

Group type: EXPERIMENTAL
Intervention: 160 mg regular megestrol acetate tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 160 mg micronized megestrol acetate tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg megestrol acetate tablet (Megace)
Number of subjects: 24
Study: 30161213

Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives
Number of subjects: 983
Study: 27405322

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study: 25202173

Group type: EXPERIMENTAL
Intervention: TA and PFM co-contraction exercise group (n=9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 15
Study: 23018469

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg every 12 hours in obese pregnant women with T2DM
Number of subjects: 17

Group type: COMPARATOR
Intervention: Metformin 850 mg every 12 hours in non-diabetic obese pregnant women with PCOS
Number of subjects: 17
Study: 19910173

Group type: EXPERIMENTAL
Intervention: Catechin (500 microg) with antitubercular treatment (ATT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Starch (500 microg) with ATT (Control)
Number of subjects: 200
Study: 18626312

Group type: EXPERIMENTAL
Intervention: MS-275 3 mg biweekly (days 1+15, arm A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MS-275 7 mg weekly (days 1+8+15, arm B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MS-275
Number of subjects: 28
Study: 16043728

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in intervention clinics, involving training in a seven-step QI change process over an 18-month period.
Number of subjects: 754

Group type: COMPARATOR
Intervention: Control clinics (no QI intervention).
Number of subjects: 754
Study: 12394910

Group type: EXPERIMENTAL
Intervention: Lumbar spine radiography
Number of subjects: 421

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study: 10422533

Group type: EXPERIMENTAL
Intervention: Faster paced trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-paced trials
Number of subjects: 0
Study: 7751822

Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lovastatin + high cholesterol diet (mean 1071 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: low cholesterol diet alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: high cholesterol diet alone
Number of subjects: 12
Study: 2255263

Group type: EXPERIMENTAL
Intervention: Oral oestriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6164789

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study: 30786997

Group type: EXPERIMENTAL
Intervention: Induction at 41 weeks
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Expectant management until 42 weeks
Number of subjects: 1801
Study: 28291046

Group type: COMPARATOR
Intervention: Deep dry needling (DDN) with no local twitch responses (LTRs) elicited
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with four LTRs elicited
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with six LTRs elicited
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) until no more LTRs were elicited
Number of subjects: 84
Study: 27025903

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 therapy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin therapy
Number of subjects: 350
Study: 24148703

Group type: EXPERIMENTAL
Intervention: Netmums Helping With Depression (NetmumsHWD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 83
Study: 22397624

Group type: EXPERIMENTAL
Intervention: Offer for a free on-line CME activity
Number of subjects: 8477

Group type: COMPARATOR
Intervention: No offer of CME credit (Control)
Number of subjects: 8477
Study: 18930988

Group type: EXPERIMENTAL
Intervention: Initial treatment with methotrexate (MTX) plus infliximab (IFX)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Delayed treatment with methotrexate (MTX) plus infliximab (IFX)
Number of subjects: 184
Study: 17444858

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol 900 IU/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: fermented papaya preparation (FPP) 9 g/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (10 healthy subjects)
Number of subjects: 50
Study: 16237479

Group type: EXPERIMENTAL
Intervention: Cannabinoid therapy
Number of subjects: 0
Study: 11866174

Group type: EXPERIMENTAL
Intervention: Nonsuicidal self-injury
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Suicide attempts
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both types of parasuicide
Number of subjects: 75
Study: 10221185

Group type: EXPERIMENTAL
Intervention: Tetracaine 1% instilled at 30 minute intervals for 24 hours
Number of subjects: 74

Group type: COMPARATOR
Intervention: Diclofenac 0.1% instilled four times a day for 3 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral Diantalvic (paracetamol-noramidopyrine) as rescue analgesic
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Visual analog pain charts
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Subjective questionnaire
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Computer analysis of photography
Number of subjects: 74
Study: 7879762

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing elastomers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional elastomers
Number of subjects: 24
Study: 2193475

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg intravenously
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 25
Study: 6998868

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 59
Study: 31747465

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study: 30348514

Group type: EXPERIMENTAL
Intervention: ALKS 3831 10/10 (10‐mg olanzapine/10‐mg samidorphan)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ALKS 3831 20/10 (20‐mg olanzapine/10‐mg samidorphan)
Number of subjects: 42

Group type: COMPARATOR
Intervention: ALKS 3831 (both doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: ALKS 3831
Number of subjects: 42
Study: 26808827

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24774670

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum CECT 7347 (10⁹ colony-forming units)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (excipients)
Number of subjects: 33